`571-272-7822
`
`
`
`
`
`
`
`
`
`Paper No. 25
`Entered: November 21, 2019
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`ADAPT PHARMA OPERATIONS LIMITED, and
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owner.
`____________
`
`IPR2019-00685, Patent 9,211,253 B2
`IPR2019-00688, Patent 9,468,747 B2
`IPR2019-00694, Patent 9,629,965 B2
`
`____________
`
`Before: ERICA A. FRANKLIN, ZHENYU YANG, and MICHAEL A.
`VALEK, Administrative Patent Judges.
`
`YANG, Administrative Patent Judge.
`
`
`
`DECISION
`Granting Patent Owner Adapt Pharma Operations Limited’s
`Motion for Pro Hac Vice Admission of Ana C. Reyes
`37 C.F.R. § 42.10
`
`
`
`
`
`
`IPR2019-00685, Patent 9,211,253 B2
`IPR2019-00688, Patent 9,468,747 B2
`IPR2019-00694, Patent 9,629,965 B2
`
`
`On November 19, 2019, in each of the three above-captioned
`
`proceedings, Patent Owner filed an Amended Mandatory Notice, adding
`
`Adapt Pharma Operations Limited (“Adapt”) as Patent Owner. Paper 19.
`
`Adapt also filed a Power of Attorney, appointing Jessamyn S. Berniker
`
`(Reg. No. 72,328) as the lead counsel. Paper 20. Adapt further filed a
`
`Motion for Pro Hac Vice Admission of Ana C. Reyes (Paper 21), supported
`
`by the Declaration of Ms. Reyes (Ex. 2038). Adapt represents that Petitioner
`
`does not oppose this Motion. Paper 21, 7.
`
`Upon review, we determine that Adapt’s Motion satisfies the
`
`requirements of 37 C.F.R. § 42.10(c), and there is good cause to admit
`
`Ms. Reyes pro hac vice in these proceedings.
`
`
`
`It is
`
`ORDERED that Adapt’s Motion for Pro Hac Vice Admission of Ana
`
`C. Reyes is granted;
`
`FURTHER ORDERED that Ms. Reyes is authorized to represent
`
`Adapt only as back-up counsel in the above-referenced proceedings;
`
`FURTHER ORDERED that Adapt is to continue to have a registered
`
`practitioner represent it as lead counsel in the above-referenced proceedings;
`
`FURTHER ORDERED that Mr. Reyes shall comply with the Office
`
`Patent Trial Practice Guide, as updated by the Office Patent Trial Practice
`
`Guide August 2018 Update, 83 Fed. Reg. 39,989 (Aug. 13, 2018) and the
`
`July 2019 Update (84 Fed. Reg. 33,925 (July 16, 2019)), and the Board’s
`
`Rules of Practice for Trials, as set forth in Part 42 of 37 C.F.R; and
`
`2
`
`
`
`
`
`IPR2019-00685, Patent 9,211,253 B2
`IPR2019-00688, Patent 9,468,747 B2
`IPR2019-00694, Patent 9,629,965 B2
`
`
`FURTHER ORDERED that Mr. Reyes shall be subject to the Office’s
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a), and the Office’s Rules
`
`of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq.
`
`
`
`
`
`PETITIONER:
`
`Yelee Kim
`Janine Carlan
`Richard Berman
`Bradford Frese
`Christopher Yaen
`yelee.kim@arentfox.com
`janine.carlan@arentfox.com
`richard.berman@arentfox.com
`bradford.frese@arentfox.com
`christopher.yaen@arentfox.com
`
`
`
`
`
`
`PATENT OWNER OPIANT PHARMACEUTICALS, INC.:
`
`Robert F. Green
`Jessica Tyrus Mackay
`rgreen@greengriffith.com
`jmackay@greengriffith.com
`
`
`
`
`
`
`
`
`3
`
`
`
`